Nutrition/Gastroenterology | Page 3 | European Cystic Fibrosis Society (ECFS)

The CFTR protein impacts energy usage in mouse brown fat

Use of the CFTR modulator combination elexacaftor/tezacaftor/ivacaftor after lung transplant

Elexacaftor-Tezacaftor-Ivacaftor (ETI) improve stomach, gullet, nose and throat symptoms in people with advanced CF

ivacaftor does not change gut bacteria, inflammation or pancreas function

Vitamin D and liver stiffness measurements – Are they players in Cystic Fibrosis liver disease?

Treatment of Idiopathic Chronic Pancreatitis (ICP) with ivacaftor in a Cystic Fibrosis (CF) carrier who also had a second inherited risk factor for pancreatitis called Methylmalonic Acidemia

Cystic fibrosis liver disease – A clinical challenge in the era of improved outcomes.

Magnetic resonance imaging of the gastrointestinal tract shows reduced small bowel motility and altered chyme in cystic fibrosis compared to controls

How ivacaftor changes inflammation and protein levels in the bloodstream of people with CF and the G551D mutation

CFTR modulator therapy alters sphingolipid profiles in blood from people with cystic fibrosis

first
previous
1
2
3
4
5
6
7
next
last